Short Interest in Elevai Labs, Inc. (NASDAQ:ELAB) Declines By 98.1%

Elevai Labs, Inc. (NASDAQ:ELAB) saw a significant decline in short interest in November. As of November 30th, there was short interest totalling 48,800 shares, a decline of 98.1% from the November 15th total of 2,620,000 shares. Based on an average trading volume of 816,600 shares, the short-interest ratio is currently 0.1 days.

Elevai Labs Stock Up 2.7 %

ELAB traded up $0.06 during midday trading on Friday, reaching $2.29. 373,113 shares of the company were exchanged, compared to its average volume of 231,465. Elevai Labs has a one year low of $1.74 and a one year high of $778.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.40 and a current ratio of 3.86. The company’s fifty day moving average price is $9.23 and its 200 day moving average price is $57.48. The company has a market cap of $5.93 million and a price-to-earnings ratio of -0.04.

Institutional Investors Weigh In On Elevai Labs

An institutional investor recently bought a new position in Elevai Labs stock. Whittier Trust Co. of Nevada Inc. acquired a new stake in Elevai Labs, Inc. (NASDAQ:ELAB) in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm acquired 80,666 shares of the company’s stock, valued at approximately $47,000. Whittier Trust Co. of Nevada Inc. owned about 0.43% of Elevai Labs as of its most recent filing with the SEC. Institutional investors and hedge funds own 22.22% of the company’s stock.

Elevai Labs Company Profile

Elevai Labs, Inc, a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc and changed its name to Elevai Labs, Inc in December 2021.